Clinical Trials Logo

Filter by:
  • Active, not recruiting  
  • Page [1] ·  Next »
NCT ID: NCT06370858 Active, not recruiting - Crohn Disease Clinical Trials

RVT-3101 for the Treatment of Moderate to Severe Active Crohn's Disease

Start date: July 24, 2023
Phase: Phase 2
Study type: Interventional

This Phase 2, randomized, double-blind, multicenter, induction and maintenance study is designed to evaluate the safety and efficacy of RVT-3101 in adult participants with moderate to severe active Crohn's disease.

NCT ID: NCT06367543 Active, not recruiting - Stroke Clinical Trials

Guideline-recommended Basic Parameter Adherence in Neurocritical Care Patients

NORMONICU
Start date: November 30, 2022
Phase:
Study type: Observational

The aim of the planned study project is to assess the current situation regarding the treatment of patients with severe stroke at the neuro-critical care unit. Specifically, determination of whether the target parameters recommended in the guidelines for temperature, systolic blood pressure, mean arterial blood pressure, blood glucose, arterial oxygen partial pressure and arterial carbon dioxide partial pressure had to be maintained. From the planned data analysis, the need for the introduction of cerebrovascular bundles can be derived and planned.

NCT ID: NCT06365827 Active, not recruiting - Acute Kidney Injury Clinical Trials

Perioperatively Assessed Biomarker I-FABP Level for Prediction of Acute Mesenteric Ischemia and Its Correlation With Acute Kidney Injury, Followed by Extracorporeal Circulation (aMIKI)

aMIKI
Start date: March 1, 2022
Phase:
Study type: Observational [Patient Registry]

Acute mesenteric ischemia (AMI) is a severe condition that might occur after cardiovascular surgery. Several risk factors for AMI, such as multimorbidity, the use of vasopressors, and an increase in inflammatory markers have been identified in the past. However, these risk factors also seem to influence the blood and urine levels of I-FABP. This prospective pilot study intends to evaluate the value of perioperatively assessed I-FABP levels and to correlate these values with clinical or angiographic findings in mesenteric ischemia to improve a standardised diagnosis.

NCT ID: NCT06311383 Active, not recruiting - Breast Cancer Clinical Trials

A Non-interventional Study for Women With HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer to Evaluate the Real-world Effectiveness of Treatment Algorithms Beginning With Ribociclib + AI/FUL, or With Endocrine Therapy or Chemotherapy as First Line Treatment

RIBANNA
Start date: October 9, 2017
Phase:
Study type: Observational

This is a non-interventional observational study conducted in Germany to evaluate the real-world effectiveness, tolerability, safety, and quality of life in patients with locally advanced/metastatic HR+/HER2- breast cancer treated with one of the following 1st line treatments: Ribociclib + AI/FUL, or endocrine monotherapy, or chemotherapy

NCT ID: NCT06266624 Active, not recruiting - HHT Clinical Trials

Tourniquet-Test in HHT

Start date: September 25, 2020
Phase: N/A
Study type: Interventional

The Tourniquet test is used as a diagnostic procedure for thrombocytopathies and vascular diseases. Currently, there is no evidence whether this test is also positive in hereditary haemorrhagic telangiectasia (HHT), a vasculopathy. The aim of this study was to investigate whether this non-invasive test could also be used as an additional diagnostic criterion in patients with HHT.

NCT ID: NCT06247683 Active, not recruiting - Cataract Senile Clinical Trials

Study to Confirm Safety and Performance of a New Multifocal IOL

Start date: March 13, 2023
Phase: N/A
Study type: Interventional

Prospective, non-comparative, multicenter study on medical device with 12 months follow-up.

NCT ID: NCT06212895 Active, not recruiting - Physical Activity Clinical Trials

Expectations of Patients Regarding Exercise in an Outpatient Clinic

Start date: December 1, 2023
Phase:
Study type: Observational

Exercise and physical activity are recommended in many clinical guidelines in orthopdeci diseases. Costs, time, doctor-patient-communication and the type of prescription are possible limitations of prescribing exercise as a therapy. It is essential to know the expactiations and attitude of the patients for an accurate, patient-centered, prescription. This trial aims to reveal patients point of view and attitude.

NCT ID: NCT06206993 Active, not recruiting - Prostate Cancer Clinical Trials

Effects of Kieser Resistance Training Plus Kieser Pelvic Floor Training vs. Kieser Resistance Training Plus Traditional Pelvic Floor Exercise on Urinary Incontinence in Prostate Cancer Patients After Radical Prostatectomy

RECON
Start date: September 1, 2019
Phase: N/A
Study type: Interventional

Surgical removal of the prostate (radical prostatectomy) is the most common therapy in prostate cancer patients. However, urinary incontinence often occurs as a side effect. Although this can recede after a few weeks or months, 12 months after prostatectomy 17 - 34 % of the patients are still incontinent. An effective measure to reduce incontinence is pelvic floor muscle or sphincter training. Various methods exist for this, from pelvic floor gymnastics to training with biofeedback devices and electrical stimulation methods. Kieser Training, a Germany-wide provider of health-oriented resistance training, has a training device for pelvic floor muscle training. It is a biofeedback device that can be used in public training rooms and does not have to be inserted or glued intimately as with comparable methods. The standardized training program and concept, which allows non-invasive training in public space, has not been evaluated yet. The aim of the RECON study is to investigate whether Kieser resistance training with integrated Kieser pelvic floor muscle training is as effective as (non-inferior to) Kieser resistance training plus conventional pelvic floor muscle exercise to reduce urinary incontinence in prostate cancer patients after radical prostatectomy. The primary endpoint is the proportion of patients with urinary incontinence at the end of a 12-week training phase (using the 24h pad test). The secondary endpoints are changes in urinary leakage, other incontinence symptoms, incontinence-related quality of life, body composition and changes in strength and overall quality of life. The design is a two-arm randomized controlled trial with 180 prostate cancer patients. After the initial examination patients will be randomized to one of two groups. Patients in both groups will train for about 60 minutes twice a week for twelve weeks and additionally perform daily tension exercises at home. Patients in group A will perform the resistance training unit with the pelvic floor biofeedback device A5 from the Kieser Training AG and patients of group B will perform the resistance training unit without the pelvic floor biofeedback device A5 and undergo conventional pelvic floor muscle training with a physiotherapist once a week before the resistance training unit starts. The Recon study will be conducted at the Kieser Training Studio in Offenbach, as a cooperation project of the National Center for Tumor Diseases (NCT), Heidelberg University Hospital and the Kieser Training AG with the Kieser Training franchisee (studio owner) as PhD student at the NCT. The Kieser Training AG is not a sponsor and the study is neither financed nor sponsored.

NCT ID: NCT06194032 Active, not recruiting - Clinical trials for Healthy Participants

A Study to Investigate the Effect on QTcF of Baxdrostat Compared With Placebo, Using Moxifloxacin as a Positive Control, in Healthy Participants

Start date: February 29, 2024
Phase: Phase 1
Study type: Interventional

This study will assess the effect of single oral doses of baxdrostat on the ECG interval measured from the onset of the QRS complex to the end of the T wave (QT) interval corrected for HR using Fridericia's formula (QTcF) compared to placebo using a concentration-QTcF analysis, and with moxifloxacin as positive control, in healthy participants.

NCT ID: NCT06169982 Active, not recruiting - Clinical trials for Diabetes Mellitus, Type 2

A Multiple Dose Study of LY3209590 in Participants With Type 2 Diabetes

Start date: December 7, 2023
Phase: Phase 1
Study type: Interventional

The purpose of this study is to measure the activity and insulin time action of LY3209590 at steady state in participants with type 2 diabetes mellitus. The total study duration is approximately 182 days.